Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

ABSTRACT:

Background

Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) and upcoming (e.g. aurora kinase inhibitors) compounds.

Design and methods

We assessed proliferation using gene expression-based indices in 757 samples including independent cohorts of 298 and 345 samples of CD138-purified myeloma cells from previously untreated patients undergoing high-dose chemotherapy, together with clinical prognostic factors, chromosomal aberrations, and gene expression-based high-risk scores.

Results

In the two cohorts, 43.3% and 39.4% of the myeloma cell samples showed a proliferation index above the median plus three standard deviations of normal bone marrow

SUBMITTER: Hose D 

PROVIDER: S-EPMC3012769 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature